A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 13, Issue 611, Pages -
Publisher
American Association for the Advancement of Science (AAAS)
Online
2021-09-16
DOI
10.1126/scitranslmed.aba7791
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer
- (2021) Steven P. Langston et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis
- (2020) Christina Cho et al. ONCOGENE
- An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles
- (2019) Angelica Ortiz et al. CANCER CELL
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
- (2019) Joseph L. Benci et al. CELL
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
- (2018) Marc L Hyer et al. NATURE MEDICINE
- SUMO2 and SUMO3 redundantly prevent a noncanonical type I interferon response
- (2018) John T. Crowl et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SUMO Safeguards Somatic and Pluripotent Cell Identities by Enforcing Distinct Chromatin States
- (2018) Jack-Christophe Cossec et al. Cell Stem Cell
- Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
- (2017) Xingyue He et al. Nature Chemical Biology
- Innate immune signaling and regulation in cancer immunotherapy
- (2016) Leticia Corrales et al. CELL RESEARCH
- The implication of SUMO in intrinsic and innate immunity
- (2016) Zara Hannoun et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Protein SUMOylation Is Required for Regulatory T Cell Expansion and Function
- (2016) Xiao Ding et al. Cell Reports
- Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing
- (2015) Adrien Decque et al. NATURE IMMUNOLOGY
- A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor
- (2015) Richard A. Klinghoffer et al. Science Translational Medicine
- Characterization of the Loss of SUMO Pathway Function on Cancer Cells and Tumor Proliferation
- (2015) Xingyue He et al. PLoS One
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity
- (2014) Haifeng C. Xu et al. IMMUNITY
- Type I Interferons Protect T Cells against NK Cell Attack Mediated by the Activating Receptor NCR1
- (2014) Josh Crouse et al. IMMUNITY
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- SUMO: A Multifaceted Modifier of Chromatin Structure and Function
- (2013) Caelin Cubeñas-Potts et al. DEVELOPMENTAL CELL
- Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy
- (2013) Serge Y. Fuchs JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Timing and Magnitude of Type I Interferon Responses by Distinct Sensors Impact CD8 T Cell Exhaustion and Chronic Viral Infection
- (2012) Yaming Wang et al. Cell Host & Microbe
- Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses
- (2012) S Bhattacharya et al. ONCOGENE
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inflammatory signaling compromises cell responses to interferon alpha
- (2011) W-C HuangFu et al. ONCOGENE
- SUMO engages multiple corepressors to regulate chromatin structure and transcription
- (2010) Jian Ouyang et al. Epigenetics
- Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8+ T cells
- (2010) Sandra Hervas-Stubbs et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
- (2010) Daniele Merico et al. PLoS One
- Complete but curtailed T-cell response to very low-affinity antigen
- (2009) Dietmar Zehn et al. NATURE
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
- (2009) Da Wei Huang et al. Nature Protocols
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started